[go: up one dir, main page]

WO2006102395A3 - Delivery systems and methods for diagnosing and treating cardiovascular diseases - Google Patents

Delivery systems and methods for diagnosing and treating cardiovascular diseases Download PDF

Info

Publication number
WO2006102395A3
WO2006102395A3 PCT/US2006/010371 US2006010371W WO2006102395A3 WO 2006102395 A3 WO2006102395 A3 WO 2006102395A3 US 2006010371 W US2006010371 W US 2006010371W WO 2006102395 A3 WO2006102395 A3 WO 2006102395A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
diagnosing
methods
delivery systems
cardiovascular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/010371
Other languages
French (fr)
Other versions
WO2006102395A2 (en
Inventor
Stephen E Epstein
Mary Susan Burnett
Martin A Mullins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
MedStar Research Institute
Original Assignee
Georgetown University
MedStar Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, MedStar Research Institute filed Critical Georgetown University
Priority to AU2006227133A priority Critical patent/AU2006227133A1/en
Priority to EP06739249A priority patent/EP1866416A2/en
Priority to CA002602946A priority patent/CA2602946A1/en
Priority to JP2008503125A priority patent/JP2008534508A/en
Publication of WO2006102395A2 publication Critical patent/WO2006102395A2/en
Publication of WO2006102395A3 publication Critical patent/WO2006102395A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Acoustics & Sound (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates relates to pharmaceutical compositions comprising a phosphorylcholine conjugate, or an antibiody preparation, for example a monoclonal antibody, with specificity to a phosphorylcholine conjugate, and the use of these compositions in the treatment or prevention of atherosclerosis, for example in the treatment, prevention or reduction of further progression of atherosclerosis. Furthermore, the invention also relates to the use of phoshorylcholine conjugates or said antibody preparation, for example monoclonal antibody to produce a pharmaceutical composition optionally with an adjuvant. Furthermore the invention relates to diagnosing the presence or absence of antibodies, for example IgM or IgG antibodies, related to increased or decreased risk of developing ischemic cardivascular diseases.
PCT/US2006/010371 2005-03-22 2006-03-22 Delivery systems and methods for diagnosing and treating cardiovascular diseases Ceased WO2006102395A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006227133A AU2006227133A1 (en) 2005-03-22 2006-03-22 Delivery systems and methods for diagnosing and treating cardiovascular diseases
EP06739249A EP1866416A2 (en) 2005-03-22 2006-03-22 Delivery systems and methods for diagnosing and treating cardiovascular diseases
CA002602946A CA2602946A1 (en) 2005-03-22 2006-03-22 Delivery systems and methods for diagnosing and treating cardiovascular diseases
JP2008503125A JP2008534508A (en) 2005-03-22 2006-03-22 Delivery system and method for diagnosing and treating cardiovascular disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66430005P 2005-03-22 2005-03-22
US60/664,300 2005-03-22

Publications (2)

Publication Number Publication Date
WO2006102395A2 WO2006102395A2 (en) 2006-09-28
WO2006102395A3 true WO2006102395A3 (en) 2007-05-10

Family

ID=36930417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/010371 Ceased WO2006102395A2 (en) 2005-03-22 2006-03-22 Delivery systems and methods for diagnosing and treating cardiovascular diseases

Country Status (6)

Country Link
EP (1) EP1866416A2 (en)
JP (1) JP2008534508A (en)
CN (1) CN101189339A (en)
AU (1) AU2006227133A1 (en)
CA (1) CA2602946A1 (en)
WO (1) WO2006102395A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
ATE555801T1 (en) * 2007-03-01 2012-05-15 Csl Ltd TREATMENT OF ENDOTHELIAL DYSFUNCTION IN DIABETES PATIENTS
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
WO2008124639A2 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
US20100239502A1 (en) * 2007-07-11 2010-09-23 Koninklijke Philips Electronics N.V. In vivo expression analysis using ultrasound-induced transfection of reporter constructs
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
GB0811856D0 (en) 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
SG175923A1 (en) * 2009-05-05 2011-12-29 Lumito Ab A system, method, and luminescent marker for improved diffuse luminescent imaging or tomography in scattering media
MX357630B (en) 2009-05-27 2018-07-17 Selecta Biosciences Inc Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents.
JP5463549B2 (en) * 2009-09-08 2014-04-09 学校法人福岡大学 Liposomes for ultrasound therapy and liposomes for promoting ultrasound therapy
US20130195764A1 (en) * 2010-04-21 2013-08-01 President And Fellows Of Harvard College Nanoparticle Targeting to Ischemia for Imaging and Therapy
WO2011135397A1 (en) * 2010-04-29 2011-11-03 University Of Calcutta Antiplatelet agent and methods of using the same
JP2013545440A (en) * 2010-09-27 2013-12-26 ヤンセン バイオテツク，インコーポレーテツド Macaca fascicularis CCL17
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
CN102657875B (en) * 2012-04-11 2013-09-04 中国人民解放军第三军医大学第二附属医院 ANT1 gene-based targeted immunoliposome, preparation method thereof and application thereof
CN103006538A (en) * 2012-11-09 2013-04-03 叶琳 Ultrasonic microbubbles for treating arthritis and use thereof
US9693958B2 (en) * 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
JP2016520595A (en) * 2013-05-22 2016-07-14 メタボリック エンジニアリング ラボラトリーズ カンパニー リミテッド Anti-TNF-α / CXCL10 double target antibody and use thereof
JP2016534114A (en) * 2013-08-21 2016-11-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング CX3CR1 targeted imaging agent and its use in disease diagnosis and treatment
CN105950660B (en) * 2016-06-27 2019-11-01 姚陈 Adenovirus vector and its application of one species specificity inhibition smooth muscle cell proliferation and migration
CN106474487A (en) * 2016-11-14 2017-03-08 中国人民解放军总医院 A kind of targeting fluorescence medicament-carried nano molecular probe and its preparation method and application
WO2019215300A1 (en) 2018-05-09 2019-11-14 Medirista Biotechnologies Ab Antibodies for use in combination therapy
CN109061139A (en) * 2018-06-19 2018-12-21 温州医科大学附属第医院 Application of the serum inflammatory biomarker in prevention and treatment acute cerebral ischemic infarction
KR20210080435A (en) * 2018-10-18 2021-06-30 다케다 야쿠힌 고교 가부시키가이샤 Methods for Activation/Proliferation of T Cells
AU2020288807B2 (en) * 2019-06-05 2025-05-08 Microvascular Therapeutics, Llc Compositions and methods of detecting and treating thrombosis and vascular plaques
CN110201194A (en) * 2019-07-23 2019-09-06 山东百多安医疗器械有限公司 A kind of load medicine contrast microbubbles and preparation method thereof for treating atherosclerotic plaque

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020701A2 (en) * 1991-05-16 1992-11-26 Miller D Douglas Interleukin receptor targeted molecules for treatment of accelerated atherosclerosis
WO1994025073A1 (en) * 1993-04-30 1994-11-10 Rhone-Poulenc Rorer S.A. Recombinant viruses and their use in gene therapy
WO1996027020A1 (en) * 1995-03-02 1996-09-06 Rhone-Poulenc Rorer S.A. Atherosclerosis gene therapy using monocyte line hdl production
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
WO2000004926A2 (en) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
WO2001010450A1 (en) * 1999-08-10 2001-02-15 Imarx Therapeutics, Inc. Targeted thrombolytic agents
WO2001032070A2 (en) * 1999-10-26 2001-05-10 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
WO2002009649A2 (en) * 2000-08-01 2002-02-07 The University Of Kansas Cell internalized peptide-drug conjugates
US20020168370A1 (en) * 1998-07-22 2002-11-14 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2003092737A1 (en) * 2002-04-30 2003-11-13 Molmed Spa Fusions of cytokines and tumor targeting proteins
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
WO2005058153A2 (en) * 2003-12-19 2005-06-30 Amersham Health As Optical imaging contrast agents comprising a targeting vector linked to a fluorophore

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
WO1992020701A2 (en) * 1991-05-16 1992-11-26 Miller D Douglas Interleukin receptor targeted molecules for treatment of accelerated atherosclerosis
WO1994025073A1 (en) * 1993-04-30 1994-11-10 Rhone-Poulenc Rorer S.A. Recombinant viruses and their use in gene therapy
WO1996027020A1 (en) * 1995-03-02 1996-09-06 Rhone-Poulenc Rorer S.A. Atherosclerosis gene therapy using monocyte line hdl production
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US20020168370A1 (en) * 1998-07-22 2002-11-14 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
WO2000004926A2 (en) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
WO2001010450A1 (en) * 1999-08-10 2001-02-15 Imarx Therapeutics, Inc. Targeted thrombolytic agents
WO2001032070A2 (en) * 1999-10-26 2001-05-10 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
WO2002009649A2 (en) * 2000-08-01 2002-02-07 The University Of Kansas Cell internalized peptide-drug conjugates
WO2003092737A1 (en) * 2002-04-30 2003-11-13 Molmed Spa Fusions of cytokines and tumor targeting proteins
WO2005058153A2 (en) * 2003-12-19 2005-06-30 Amersham Health As Optical imaging contrast agents comprising a targeting vector linked to a fluorophore

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BELIZAIRE A-K ET AL: "Identification of a murine ICAM-1-specific peptide by subtractive phage library selection on cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 309, no. 3, 26 September 2003 (2003-09-26), pages 625 - 630, XP004453645, ISSN: 0006-291X *
DEMOS S M ET AL: "In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions", JOURNAL OF DRUG TARGETING, vol. 5, no. 6, 1998, pages 507 - 518, XP008074992, ISSN: 1061-186X *
DENEFLE P P ET AL: "TOWARDS GENE THERAPY TARGETING HDL", INTERNATIONAL CONGRESS SERIES, EXCERPTA MEDICA, AMSTERDAM, NL, October 1994 (1994-10-01), pages 501 - 505, XP000572778, ISSN: 0531-5131 *
LUTTERS B C H ET AL: "Blocking endothelial adhesion molecules: A potential therapeutic strategy to combat atherogenesis", CURRENT OPINION IN LIPIDOLOGY, vol. 15, no. 5, 2004, pages 545 - 552, XP008074993, ISSN: 0957-9672 *
VILLANUEVA ET AL: "Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells", CIRCULATION, vol. 98, no. 1, 7 July 1998 (1998-07-07), pages 1 - 5, XP002092048, ISSN: 0009-7322 *
WELLER GREGORY E R ET AL: "Modulating targeted adhesion of an ultrasound contrast agent to dysfunctional endothelium.", ANNALS OF BIOMEDICAL ENGINEERING, vol. 30, no. 8, September 2002 (2002-09-01), pages 1012 - 1019, XP007901749, ISSN: 0090-6964 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver
US11547746B2 (en) 2016-12-15 2023-01-10 Talengen International Limited Method for treating coronary atherosclerosis and complications thereof

Also Published As

Publication number Publication date
WO2006102395A2 (en) 2006-09-28
EP1866416A2 (en) 2007-12-19
CN101189339A (en) 2008-05-28
AU2006227133A1 (en) 2006-09-28
CA2602946A1 (en) 2006-09-28
JP2008534508A (en) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2006102395A3 (en) Delivery systems and methods for diagnosing and treating cardiovascular diseases
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
UA102667C2 (en) Human neutralizing anti b7rp1 antibody
LUC00053I2 (en) ANTIBODIES AGAINST CD38 FOR THE TREATMENT OF MULTIPLE MYELOMA
WO2008116219A3 (en) Uses of monoclonal antibody 8h9
WO2007022520A3 (en) Antibody-mediated enhancement of immune response
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2009112245A9 (en) Antibody against the csf-1 r
BRPI0611414B8 (en) antibody or antigen-binding fragment thereof that binds to human tweak, pharmaceutical composition and its uses
WO2006044643A3 (en) Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006099698A3 (en) Novel anti-plgf antibody
WO2019215510A3 (en) Compositions and methods related to anti-cd19 antibody drug conjugates
NZ595235A (en) Compositions and methods for increasing muscle growth
MX2009004532A (en) Compositions and methods for binding sphingosine-1-phosphate.
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
WO2009083009A3 (en) Monoclonal antibodies against cd32b
NO20071436L (en) Humanized Anti-5T4 Antibodies and Anti-5T4 Antibody / Calicheamicin Conjugates
TW200642694A (en) Anti-M-CSF antibody compositions
WO2006122257A3 (en) Nebulization of monoclonal antibodies for treating pulmonary diseases
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
EP2684889A3 (en) Multivariable antigens complexed with targeting humanized monoclonal antibody
EA200600275A1 (en) CYTOTOXIC CONJUGAT, SPECIFICALLY RELATED TO CA6 ANTIGEN, AND METHODS OF ITS APPLICATION
WO2010066803A3 (en) Human antibodies against human tissue factor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680013593.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2602946

Country of ref document: CA

Ref document number: 2008503125

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006227133

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006739249

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 4051/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006227133

Country of ref document: AU

Date of ref document: 20060322

Kind code of ref document: A